CEI Campus Moncloa, UCM-UPM & CSIC, Madrid, Spain; Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Pza. Ramón y Cajal s/n, Madrid 28040, Spain.
Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, Pza. Ramón y Cajal s/n, Madrid 28040, Spain.
Exp Parasitol. 2015 Feb;149:84-91. doi: 10.1016/j.exppara.2015.01.002. Epub 2015 Jan 9.
Solid dispersions (SD) of benznidazole (BNZ) in sodium deoxycholate (NaDC) or low-substituted hydroxypropylcellulose (L-HPC) were developed by freeze-drying process to improve the solubility of this low water-soluble drug and consequently, its trypanocidal activity. Although the dissolution studies showed a progressive decrease in the release rate of BNZ when formulated in the presence of NaDC, the increase in the surfactant concentration resulted in a better trypanocidal profile on epimastigotes, as well as in an enhancement of the unspecific cytotoxicity. However, such an effect was not so evident on amastigotes and in vivo (blood-trypomastigotes), where high concentrations of surfactant (BNZ:NaDC ≥ 1:6) experimented a loss of activity, correlating this fact with the minor cession of BNZ these formulations accomplished in acidic locations (i.e., dissolution test medium). According to the in vitro results, we reformulated the promising SD-1:3 (IC₅₀ epimastigotes = 33.92 ± 6.41 µM, IC₅₀ amastigotes = 0.40 ± 0.05 µM and LC₅₀ = 183.87 ± 12.30 µM) replacing NaDC by L-HPC, which achieved the fastest dissolution profile. This fact, together with the safety this carrier ensures (LC₅₀ > 256 µM), prompted us to evaluate the cellulose SD in vivo, improving the effectiveness of its NaDC equivalent (%AUPC = 96.65% and 91.93%, respectively). The results compiled in the present work suggest these solid dispersions as alternative drug delivery systems to improve the limited chemotherapy of Chagas disease.
采用冷冻干燥法制备了苯硝唑(BNZ)在脱氧胆酸钠(NaDC)或低取代羟丙基纤维素(L-HPC)中的固体分散体,以提高这种低水溶性药物的溶解度,从而提高其杀锥虫活性。虽然溶解研究表明,当用 NaDC 配制时,BNZ 的释放率逐渐降低,但表面活性剂浓度的增加导致对前鞭毛体的杀锥虫谱更好,以及非特异性细胞毒性增强。然而,这种效应在无鞭毛体和体内(血液-锥鞭毛体)中并不那么明显,在这些部位,高浓度的表面活性剂(BNZ:NaDC ≥ 1:6)会失去活性,这与这些制剂在酸性部位(即溶解试验介质)中 BNZ 的含量减少有关。根据体外结果,我们用 L-HPC 替代有前途的 SD-1:3(IC₅₀ 前鞭毛体= 33.92 ± 6.41 μM,IC₅₀ 无鞭毛体= 0.40 ± 0.05 μM 和 LC₅₀ = 183.87 ± 12.30 μM)重新配制了 SD-1:3,从而实现了最快的溶解曲线。这一事实,再加上这种载体所保证的安全性(LC₅₀ > 256 μM),促使我们在体内评估纤维素 SD,提高其 NaDC 等效物的有效性(%AUPC = 96.65%和 91.93%)。本工作中总结的结果表明,这些固体分散体可以作为改善恰加斯病有限化疗的替代药物传递系统。